ASCO Annual Meeting | Conference

Pembrolizumab 3-Year Survival Rate Hits 40% in Melanoma

May 19th 2016

Forty percent of patients with advanced melanoma who started taking pembrolizumab during the clinical trial that led to its initial approval were still alive after 3 years, with many responders in remission even after stopping treatment.

Stem Cell Transplant Continues to Show Benefit in 'Novel-Agent Era' of Multiple Myeloma

May 19th 2016

Early findings from a phase III clinical trial suggest that patients with multiple myeloma who receive upfront autologous stem cell transplant survive longer without disease progression than those who receive chemotherapy alone.

Tumor Location Linked to Survival Outcomes in Metastatic Colorectal Cancer

May 19th 2016

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

Early Integration of Palliative Care Improves Outcomes for Family Caregivers

May 19th 2016

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

Outcomes Better With Biomarker-Based Therapies in Phase I Studies

May 19th 2016

Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.

Practical Advice for Immunotherapy Era Emerges From ASCO

June 22nd 2015

For clinicians, a central message from 2015 ASCO is that a framework for managing immune-related adverse events in patients who receive these immune checkpoint agents is taking shape.

ASCO 2015: Immuno-Oncology Again Takes Center Stage

June 16th 2015

The ASCO annual meeting has retained its core purpose of providing a unique platform for oncologists to interact and exchange the latest practice-changing research.

Frontline BRAF/MEK Combo Improves Survival in Melanoma

June 11th 2015

Combination MEK/BRAF inhibition with trametinib and dabrafenib reduced the risk of death by 29% in patients with BRAF-mutant advanced melanoma.

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

June 10th 2015

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

June 10th 2015

Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

June 9th 2015

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Stefani Spranger on β-Catenin Signaling and Overcoming Immunotherapy Resistance

June 8th 2015

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic β-Catenin Committee, discusses the effect of melanoma intrinsic β-catenin signaling on immune exclusion and resistance to immunotherapies.

Triplet Therapy Effective in BRAF-mutant mCRC

June 8th 2015

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Lenvatinib Plus Everolimus Improves Survival in mRCC

June 5th 2015

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dr. Manish Shah on the METGastric Study

June 4th 2015

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

NEXT PAGE
PREVIOUS PAGE